KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Acquisitions & Divestments (2017 - 2025)

Historic Change in Acquisitions & Divestments for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q3 2025 value amounting to $113.5 million.

  • Xenon Pharmaceuticals' Change in Acquisitions & Divestments fell 3127.69% to $113.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $616.2 million, marking a year-over-year decrease of 824.92%. This contributed to the annual value of $700.3 million for FY2024, which is 177.35% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $113.5 million for Q3 2025, which was down 3127.69% from $171.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $235.7 million during Q2 2024, with a 5-year trough of $20.3 million in Q1 2022.
  • In the last 5 years, Xenon Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $133.8 million in 2024 and averaged $118.1 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Change in Acquisitions & Divestments plummeted by 5586.99% in 2022 and then soared by 67470.41% in 2023.
  • Xenon Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $42.3 million in 2021, then soared by 147.8% to $104.8 million in 2022, then surged by 30.66% to $136.9 million in 2023, then increased by 21.01% to $165.6 million in 2024, then plummeted by 31.47% to $113.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $113.5 million for Q3 2025, versus $171.2 million for Q2 2025 and $165.8 million for Q1 2025.